controversies to consensus in diabetes, obesity and ... - CODHy
controversies to consensus in diabetes, obesity and ... - CODHy
controversies to consensus in diabetes, obesity and ... - CODHy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
1 st Asia Pacific Congress on Controversies <strong>to</strong> Consensus <strong>in</strong> Diabetes, Obesity <strong>and</strong> Hypertension (<strong>CODHy</strong>)<br />
Shanghai • Ch<strong>in</strong>a • June 2-5, 2011<br />
M. Hanefeld<br />
Germany<br />
CO-CHAIRPERSONS<br />
L. Ji<br />
Ch<strong>in</strong>a<br />
G. N<strong>in</strong>g<br />
Ch<strong>in</strong>a<br />
I. Raz<br />
Israel<br />
S.M. Sadikot<br />
India<br />
ORGANIZING COMMITTEE<br />
A. Ceriello, UK<br />
J. Chan, Ch<strong>in</strong>a<br />
J. Davidson, USA<br />
R.A. DeFronzo, USA<br />
S. Del Pra<strong>to</strong>, Italy<br />
V.A. Fonseca, USA<br />
V. Ha<strong>in</strong>er, Czech Republic<br />
P. Home, UK<br />
N. Hotta, Japan<br />
W. Lee, S<strong>in</strong>gapore<br />
P.M. Nilsson, Sweden<br />
A. Ramach<strong>and</strong>ran, India<br />
SCIENTIFIC COMMITTEE<br />
M. Al-Arouj, Kuwait<br />
R. Bitzur, Israel<br />
B. Bonora, Italy<br />
C. Cockram, Hong Kong<br />
J.H. de Vries, The Netherl<strong>and</strong>s<br />
A. de Zeeuw, The Netherl<strong>and</strong>s<br />
M. Donath, Switzerl<strong>and</strong><br />
R. Fagard, Belgium<br />
B. Frier, UK<br />
B. Gallwitz, Germany<br />
E. Grossman, Israel<br />
S. Heller, UK<br />
B. Hirshberg, Israel<br />
P. Iozzo, Italy<br />
A. Kadir, Malaysia<br />
A. Keidar, Israel<br />
L. Keuky, Cambodia<br />
A. Khan, Bangladesh<br />
Y. Kun-Ho, Korea<br />
M. Laakso, F<strong>in</strong>l<strong>and</strong><br />
N.M. Lalic, Serbia<br />
H. Lebowitz, USA<br />
L.A. Leiter, Canada<br />
S. Madsbad, Denmark<br />
D.M. Mann<strong>in</strong>o, USA<br />
J. Meigs, USA<br />
L. Menegh<strong>in</strong>i, USA<br />
D. Micic, Serbia<br />
A. Natali, Italy<br />
M.A. Nauck, Germany<br />
A.K. Nikousokhan, Iran<br />
W. Nitiyanant, Thail<strong>and</strong><br />
U. Pagot<strong>to</strong>, Italy<br />
D. Pei, Taiwan<br />
P. Pozzilli, Italy<br />
M.T. Que, The Philipp<strong>in</strong>es<br />
P. Rask<strong>in</strong>, USA<br />
F. Rub<strong>in</strong>o, USA<br />
L.M. Ruilope, Spa<strong>in</strong><br />
W. Scherbaum, Germany<br />
G. Schernthaner, Austria<br />
S. Soegondo, Indonesia<br />
E. St<strong>and</strong>l, Germany<br />
P. Tønnesen, Denmark<br />
D. Tschöpe, Germany<br />
C. Tsigos, Greece<br />
J. Tuomileh<strong>to</strong>, F<strong>in</strong>l<strong>and</strong><br />
T. Vilsbøll, Denmark<br />
R. Weiss, Israel<br />
B. Wolffenbuttel, The Netherl<strong>and</strong>s<br />
J.T. Woo, Korea<br />
A. Zanchetti, Italy<br />
D. Ziegler, Germany<br />
INDUSTRY ADVISORY BOARD (IAB)<br />
S. Basavappa, Takeda<br />
R. Chaiken, Pfizer<br />
J. Chan, Eli Lilly<br />
E. Fan, Roche<br />
G. Giazzon, Takeda<br />
H. Gr<strong>in</strong>golts, Johnson & Johnson<br />
A. Grooten, Boehr<strong>in</strong>ger Ingelheim<br />
B. Hirshberg, Astra Zeneca<br />
H. Katzeff, Merck<br />
L. Lee, Janssen Cilag<br />
S. Nagendran, Daichii Sankyo<br />
C. Rond<strong>in</strong>one, Roche<br />
M. Von Eynatten, Boehr<strong>in</strong>ger Ingelheim<br />
A. Xu, Eli Lilly<br />
T. Yu, Novo Nordisk<br />
K. Zhang, Novo Nordisk<br />
5
Change language